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Imaging is used to detect, characterize, and monitor cancer. Recently, diffusion-weighted magnetic resonance imaging (DWI) has become a useful adjunct for assessing tumors with magnetic resonance imag-
ing (MRI). DWI involves the acquisition of a magnetic resonance sig-
nal related to random thermal motion (Brownian motion) or the “dif-
fusion” of water protons in tissue. The signal obtained with DWI is a 
measure of the net displacement of water molecules, e.g., the water path 
length in the extracellular, intracellular and intravascular spaces. This 
motion is largely random and can be reduced by structural barriers, such 
as cell membranes and collagen. Restricted diffusion in biological tis-
sues is inversely proportional to tissue cellularity and the integrity of 
cell membranes, and it can be quantified with apparent diffusion coef-
ficient (ADC) measurements (1). Depending on the microarchitecture, 
either restricted or increased diffusion can occur in malignant tumors. 
For instance, diffusion is restricted in cellular portions of the tumor, but 
it may be increased in necrotic portions (2, 3). Other causes of enhanced 
diffusion include increased water content arising from intratumoral ede-
ma and cystic tumor components (4–6).
Although initially used to evaluate neurological diseases, the appli-
cations of DWI have been extended to oncologic imaging throughout 
the body made possible by improvements in MRI hardware and new 
sequences. The use of DWI as a complement to conventional MRI meth-
ods has led to improvements in the detection and characterization of 
tumors, treatment response monitoring, and detection of recurrence in 
oncology patients.
Basic concepts of DWI
In 1965, Stejskal and Tanner (7) proposed the application of a sym-
metric pair of additional gradients on either side of the 180˚ refocusing 
radiofrequency pulse. The Stejskal-Tanner sequence is still the basis of 
modern DWI. For static water molecules, the phasing effect caused by 
the first gradient will be reversed by the second gradient, leading to no 
signal loss; however, this phasing effect will not be completely reversed 
if the water molecules are not stationary, which results in the observed 
well-known diffusion signal decay. The amount of diffusion weighting 
is determined by the b value, which describes the amplitude, duration 
of the applied gradient, and time interval between the two diffusion gra-
dients (4). The degree of signal attenuation from water molecules is cor-
related with the b value. Low b values indicate flow or perfusion move-
ment, whereas high b values (e.g., b=1.000 s/mm2) indicate slow-moving 
water molecules (1). A minimum of two b values are necessary for DWI 
and the calculation of ADC. The evaluation of the data provided by DWI 
can be either qualitative or quantitative. Qualitative evaluation involves 
visually assessing the relative signal intensity attenuation of images 
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ABSTRACT
Diffusion-weighted magnetic resonance imaging (MRI), 
which involves the acquisition of a magnetic resonance signal 
related to the Brownian motion of water protons in tissue, 
has become a useful technique for assessing tumors. In this 
article, we review the basic concepts, imaging strategies, and 
body applications of diffusion-weighted MRI in detecting and 
monitoring cancer.
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also known as diffusion-weighted 
“rapid acquisition with relaxation 
enhancement” (9) and “half-Fourier-
acquisition single-shot turbo-spin-
echo” (HASTE) sequences, and the 
recently proposed diffusion-weighted 
periodically rotated overlapping par-
allel lines with enhanced reconstruc-
tion (PROPELLER) sequence can also 
be used for DWI. These sequences are 
very fast and less prone to motion arti-
facts, although their spatial resolution 
is limited (8).
In DWI, the two greatest sources of 
image degradation are magnetic field 
inhomogeneity and motion artifacts. 
The main strategies used to improve 
image quality are breath-hold single-
shot DWI and non-breath-hold mul-
tiple-averages DWI. DWI can also be 
performed at one location or at multi-
ple stations, in which case the images 
can be “stitched” together to create 
a whole-body image (also known as 
diffusion-weighted whole-body imag-
ing with background body signal sup-
pression [DWIBS]) (4). The breath-hold 
DWI technique involves the quick ac-
quisition of an image within a limited 
number of breath-holds. The speed is 
increased by using very short single-
shot EPI echo times with parallel im-
aging and fat suppression (4, 10, 11). 
Moreover, respiratory motion and vol-
ume averaging artifacts can be reduced. 
However, single-shot breath-hold EPI 
also has some inherent limitations, 
such as the limited number of b values 
that can be acquired within the dura-
tion of a single breath-hold, reduced 
signal-to-noise ratio, and greater sensi-
tivity to pulsatile and susceptibility ar-
tifacts (4). Non-breath-hold sequences, 
such as the non-breath-hold spin-echo 
EPI combined with fat suppression, 
can also be used for body DWI studies 
(4). The advantage of these sequences 
is the higher spatial resolution they 
provide. The technique improves the 
signal-to-noise and contrast-to-noise 
ratios by means of multiple-slice ex-
citation and signal averaging over a 
longer duration (12). However, it is as-
sociated with a longer scanning time 
(3 to 6 min), which enables the use of 
multiple (>5) b values (2, 4). DWIBS is 
performed using a short tau inversion 
recovery (STIR) EPI technique with a 
high b value (1 000 s/mm2) for back-
ground suppression. Free-breathing, 
multiple-averaging DWI is performed 
at contiguous stations in the body, and 
a composite image of the whole-body 
maximum intensity projection is dis-
played with an inverted gray scale on 
a white background (12). Although the 
signals from normal tissue (e.g., blood 
vessels, fat, muscle, and bowel) are sup-
pressed, other normal structures (e.g., 
the spleen, prostate, testes, and ova-
ries) remain visible (12). The technique 
depicts tumors and some benign proc-
esses, such as abscesses, with areas of 
restricted diffusion (4). Additionally, 
the technique has been reported to 
be capable of depicting small foci of 
tumors within the abdomen or perito-
neum (12). Similar to the non-breath-
hold technique, multiple-averaging 
DWI, e.g., DWIBS, offers the advantag-
es of thin image partitions and a good 
signal-to-noise ratio. Nevertheless, the 
relatively long image acquisition time 
required to evaluate the whole body is 
a disadvantage.
In living organs, there are many 
ways to keep water molecules moving. 
Two of these are of particular relevance 
to DWI: the well-recognized thermally 
driven diffusion and the less-valued 
blood flow in the microvasculature 
(pseudodiffusion). The diffusion of wa-
ter molecules is more restricted within 
a cell than outside because of the ex-
istence of cell membranes. Because the 
ADC reflects the diffusion from both 
intracellular and extracellular environ-
ments, this measure would be largely 
decreased if the extracellular space was 
to some extent compressed, leading to 
more weight on the intracellular por-
tion of the ADC. As tumors aggressively 
grow, the number of tumor cells greatly 
increases (causing higher cellularity). 
These less-organized cells are closely 
compressed, leading to reduced extra-
cellular space, which in turn results in 
a lower ADC. This phenomenon forms 
the basis for using ADC as a surrogate 
biomarker for tumor detection. In the 
1980s, Le Bihan et al. (13) proposed a 
seminal theoretical model known as 
intravoxel incoherent motion (IVIM) 
MRI, which aimed to separate the ac-
tive blood microcirculation (perfusion) 
from molecular diffusion in DWI. The 
water molecules in a capillary network 
mimic those engaging in Brownian 
motion because of the randomly or-
ganized capillary environments; how-
ever, each group of molecules exhib-
its distinct time and spatial scales to 
produce a pseudodiffusion coefficient 
one or two magnitudes larger than 
obtained at different b values and ena-
bles tissue characterization based on 
differences in water diffusion (1, 4). 
From a clinical point of view, qualita-
tive assessment can help to detect and 
characterize tumors, monitor the treat-
ment response, and detect recurrence 
in patients with cancer. Trace or index 
diffusion-weighted images are the sum 
of images acquired by applying diffu-
sion gradients in each of the three or-
thogonal directions. The signal inten-
sity in these images is affected by both 
water diffusion and T2 relaxation time; 
thus, a tissue area with a very long 
T2 relaxation time may reveal a high 
signal that may be misinterpreted to 
represent restricted diffusion at DWI, 
a phenomenon that is also known as 
“T2 shine-through” (4). An additional 
entity is the “T2 dark-through” effect, 
which indicates hypointensity in both 
DWI and T2W MRI. Such effects, main-
ly secondary to susceptibility effects, 
are commonly seen in hematomas. 
The use of appropriate TE and b values 
may reduce these effects.
In biological tissues, a quantitative 
analysis of DWI can be performed by 
calculating an ADC based on the rela-
tive signal intensity change of the tis-
sue with increasing b values (4). ADC 
maps are based on the slope of the line 
depicting signal loss with rising b val-
ues. Values can be calculated on a vox-
el-by-voxel basis to provide ADC maps. 
Notably, restricted diffusion in highly 
cellular areas results in low ADC val-
ues compared with less cellular areas, 
which show higher ADC values.
Imaging strategies
Virtually any type of pulse sequence 
can be adapted for body DWI. These 
include spin-echo, stimulated-echo, 
echo-planar (EPI), turbo-spin-echo 
(TSE), and steady-state free-precession 
sequences. In general, the most pop-
ular pulse sequence for DWI is the 
single-shot spin-echo EPI sequence, 
which is less prone to motion artifacts. 
However, this technique has the inher-
ent disadvantage of image distortion 
because of susceptibility artifacts and 
low spatial resolution, both of which 
limit its use in areas other than the 
brain (8). Recently, improvements in 
gradient systems and the application 
of parallel imaging techniques have 
improved the suitability of EPI for 
body DWI. Diffusion-weighted single-
shot fast-spin-echo (or TSE) sequences, 
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coefficient of its counterpart. Initially, 
IVIM was applied to neuroimaging. In 
recent years, however, IVIM has at-
tracted renewed attention for body/
oncology applications because of high-
er available magnetic fields and better 
gradient hardware performance, which 
facilitates faster data acquisition and 
generates images of superior quality. 
Most importantly, IVIM has the poten-
tial to provide information about both 
the cellularity and perfusion of tumors; 
aggressive tumor growth is intrinsical-
ly associated with a higher number of 
tumor cells and greater angiogenesis. 
With the increasing awareness of the 
toxicity of MR contrast agents, IVIM 
could be considered a favorable alter-
native for deriving perfusion informa-
tion without contrast agent injection 
(13–17).
Optimization of the technique
The optimization of the scanning pa-
rameters helps to improve the signal- 
and contrast-to-noise ratio between 
the tumor and surrounding tissue. Fat 
suppression with an inversion recov-
ery (e.g., STIR) technique is preferred 
for DWI when the field of view is large, 
whereas chemical-fat-selective satura-
tion (e.g., spectral-selected attenua-
tion with inversion recovery [SPAIR] or 
chemical-shift-selective  [CHESS] imag-
ing) or water-selective excitation may 
be used for selected body regions (4). In 
general, the acquisition time should be 
as short as possible. Moreover, the rep-
etition time should be long enough to 
minimize T1 saturation effects, which 
would otherwise generate falsely low 
ADC values. The adapted b values 
for body imaging should typically be 
lower than those for brain DWI, thus 




With the rising concern about the 
effects of ionizing radiation from com-
puted tomography (CT) imaging, DWI 
has been increasingly applied to pedi-
atric populations. Experience is still 
limited, and most reports describe only 
initial experiences when using DWI as 
a part of pediatric MRI. In a small se-
ries, seven children with neuroblasto-
mas demonstrated significantly higher 
contrast with DWI than with T2W 
MRI. The ADC was correlated with the 
tumor cellularity as revealed in the 
histology examination. It was suggest-
ed that DWI was helpful in the differ-
ential diagnosis of neuroblastoma and 
outlined the tumor better than other 
MRI techniques (18). This observation 
was validated in a study of 19 pediatric 
patients presenting with a variety of 
tumors; in that study, ADC values were 
not helpful in distinguishing malig-
nant from benign lesions (19). Alibek 
et al. (20) reported the largest pediatric 
experience to date (n=29) and showed 
that DWI correlated well with post-Gd 
T1W MRI in a variety of tumors, which 
therefore suggested that DWI might be 
a useful substitute in patients with ad-
vanced renal insufficiency. In a study 
of DWI in osteosarcoma, a significant 
increase in the ADC value was corre-
lated with the tumor necrosis grade 
after chemotherapy, suggesting that 
ADC measurements might be a quan-
titative tool for assessing the response 
(Fig. 1) (21). Whole-body DWI is com-
pelling because it can cover large re-
gions of the body without requiring 
ionizing radiation (22). Thus, as a safe, 
radiation-free and noninvasive tool, 
DWI holds promise for a broad range 
of pediatric malignancies.
Thoracic applications
MRI of the lung using fast acquisi-
tion sequences with a high temporal 
resolution has become feasible with 
the recent developments in gradi-
ent technology, multichannel coils, 
and parallel imaging techniques (23). 
Experience with thoracic applications 
of DWI techniques is still growing, 
and preliminary studies have reported 
promising results (24–35).
In the chest, DWI is typically ac-
quired in a transverse plane, using at 
least two b values. Most studies em-
ploy the combination of low (0–50 s/
mm2) and intermediate-to-high b val-
ues (400–1000 s/mm2). Higher b val-
ues generate more diffusion weight-
ing at the expense of a reduced signal. 
Usually, diffusion gradients are applied 
in three directions to improve scanning 
efficiency. The STIR approach has been 
most commonly used for fat suppres-
sion to achieve a more accurate ADC 
estimation. Early studies employed free 
breathing or breath holding (24–35). 
The latter type of study can be com-
pleted in two or more separate breath-
holding scans. Respiratory or ECG gat-
ing has been used, but typically only at 
the lesion site rather than for the entire 
chest (25–27). The typical slice thick-
ness is 4–9 mm with an interslice gap 
of 0–1.5 mm, and the number of ex-
citations ranges from 1 to 10. Phased-
array surface coils are preferred because 
they improve the signal-to-noise ratio 
and allow parallel imaging, which re-
duces the acquisition time.
Chest DWIs can be evaluated qualita-
tively, semiquantitatively, and quanti-
tatively. In qualitative evaluations, the 
chest wall muscles or spinal cord can 
be used as a standard of reference when 
evaluating the signal intensity of a tar-
get lesion (24, 27, 28, 36). Malignant 
lesions tend to be hyperintense rela-
tive to the chest wall muscles or spi-
nal cord. Semiquantitative evaluation 
is performed by measuring the signal 
intensities of the lesion and comparing 
them with the spinal cord or chest wall 
muscles. The calculated ratio of the sig-
nal intensity of the lesion to that of the 
spinal cord has been used to differenti-
ate between benign and malignant tu-
mors (29). Quantitative DWI analysis 
relies on ADC measurement. A circular 
or elliptical region of interest (ROI) is 
drawn on the section where the tar-
get lesion was detected on the T2W or 
contrast-enhanced images. In hetero-
geneous tumors, care should be taken 
to place the ROI in the solid portion of 
the mass, excluding cystic or necrotic 
areas. DWI has been used to charac-
terize lung lesions (27), to detect and 
classify adenocarcinomas (37), to pre-
dict tumor invasiveness in early-stage 
lung cancer (24), to detect tumors in 
collapsed lungs (32, 33), and for nodal 
staging of lung cancer (26, 35).
Most malignant lesions tend to be 
hyperintense relative to the chest wall 
muscles or the spinal cord on DWI im-
ages and hypointense on ADC maps 
(Fig. 2). In a series of 51 patients with 
54 nodules, Satoh et al. (36) compared 
the signal intensity of nodules with that 
of the spinal cord and found that ma-
lignant nodules were significantly more 
hyperintense than benign nodules. The 
authors reported 89% sensitivity, 61% 
specificity, and 89% accuracy when the 
signal intensity of nodules was equal to 
or greater than that of the spinal cord. 
In contrast, Liu et al. (28) did not find 
significant signal intensity differences 
between benign and malignant nodules 
in an analysis of 66 pulmonary lesions. 
However, they reported 83% sensitivity 
and 74% specificity using a threshold 
ADC value of 1.4×10-3 mm2/s. Kanauchi 
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et al. (24) investigated tumor invasive-
ness with qualitative DWI in 41 pa-
tients with stage IA non-small cell lung 
carcinoma using lesion-to-spinal-cord 
ratios (LSR). It was reported that DWI 
was an independent predictive factor 
for tumor aggressiveness. In a series of 
28 patients, Uto et al. (29) compared 
the performance of LSR signal intensity 
with that of ADC and found that LSR 
was more accurate in distinguishing 
malignant from benign nodules. Using 
an LSR threshold of 1.135, they report-
ed 83% sensitivity, 90% specificity, and 
86% accuracy. ADC values have also 
had favorable results, with a sensitivity 
of 33%–84% and a specificity of 74%–
100% (23, 28–30).
Figure 1. a–f. Axial T2W STIR (a), T1W TSE (b), T1W VIBE Gd enhanced (c), TRUFI (d), DWI (b=1000 s/mm2) (e), and ADC map (f) show 
tumor margins in an 11-year-old patient with osteosarcoma of the rib (arrows). The highest lesion in relation to the background contrast is 
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Quantitative DWI has also been used 
for the tissue characterization of lung 
cancers. Matoba et al. (27) reported 
that the mean ADC value of adenocar-
cinoma was significantly higher than 
that of squamous cell carcinoma or 
large cell carcinoma (2.1×10-3 mm2/s 
vs. 1.6×10-3 mm2/s vs. 1.3×10-3 mm2/s, 
respectively). It was also reported that 
the mean ADC value of well-differenti-
ated adenocarcinoma was significantly 
higher than the values for moderately 
and poorly differentiated squamous 
cell carcinoma and poorly differenti-
ated adenocarcinoma. This finding 
is supported by Mori et al. (30), who 
reported that 39.6% (21/53) of well-
differentiated adenocarcinoma was 
negative on DWI, compared with 4.7% 
(1/21) of squamous cell carcinoma. On 
the contrary, Koyama et al. (37) report-
ed that quantitative DWI is less sen-
sitive than STIR in the detection and 
subtype classification of pulmonary 
adenocarcinomas, particularly bron-
chioalveolar carcinoma. Therefore, 
DWI should always be evaluated in 
conjunction with conventional MRI 
sequences.
Another application of DWI is tumor 
detection in collapsed lungs, which is 
difficult with conventional modali-
ties. The precise differentiation of the 
tumor from post-obstructive consoli-
dation is important for clinical stag-
ing and radiotherapy planning. Qi et 
al. (32) compared the performance 
of T2W MRI, DWI, and contrast-en-
hanced CT in 33 cases of suspected 
lung cancer and post-obstructive 
consolidation. The authors were able 
to differentiate cancer from consolida-
tion on CT, T2W MRI, and DWI in 14, 
21, and 26 patients, respectively. The 
combination of T2W MRI and DWI 
differentiated 88% (29/33) of cases, 
with higher interobserver agreement 
for DWI. Similarly, Baysal et al. (33) re-
ported that the mean ADC of the cen-
tral mass was significantly lower than 
that of post-obstructive consolidation.
Quantitative DWI has also been used 
to assess mediastinal lymph nodes. In 
an evaluation of 734 lymph nodes in 
88 patients with non-small-cell lung 
carcinoma, Nomori et al. (35) reported 
a sensitivity of 70% and a specificity 
of 97% using an ADC cutoff value of 
1.6×10-3 mm2/s. Similarly, Kosucu et 
al. (26) reported that the ADC of meta-
static lymph nodes was significantly 
lower than that of benign nodes. 
Nakayama et al. (38) calculated the 
ADC difference between a lung cancer 
and a lymph node in 70 patients with 
non-small-cell lung cancer and found 
that the mean ADC difference in the 
lymph node group with metastases 
was significantly lower than that in 
the group without metastases. Using 
an ADC difference of 0.24×10-3 mm2/s 
as a positive test threshold, the authors 
reported that the sensitivity, specifici-
ty, and accuracy were 69%, 100%, and 
94%, respectively.
DWI has compared favorably to pos-
itron emission tomography (PET). In 
a series of 140 nodules/masses, Mori 
et al. (30) reported that the sensitiv-
ity of DWI was comparable to that of 
PET (70% vs. 72%), and its specificity 
was significantly higher (97% vs. 79%) 
because of fewer false positives for ac-
tive inflammatory lesions with DWI. 
Nomori et al. (35) did not find a signif-
icant difference in the sensitivity, but 
DWI had significantly fewer false nega-
tive results (5/698 vs. 18/698), which 
resulted in higher specificity. Ohba et 
al. (39) found that DWI was compara-
ble to PET in distinguishing non-small-
cell lung cancer from benign pulmo-
nary nodules in 110 patients with 124 
pulmonary nodules. 
DWI has evolved into a diagnostical-
ly useful tool for the characterization 
of pulmonary nodules and mediastinal 
lymph nodes. Potential future applica-
tions of DWI in lung cancer include 
monitoring the treatment response 
after chemotherapy or radiation, dis-
criminating post-therapeutic changes 
from residual tumors, and detecting 
recurrent cancer.
Breast applications
DWI has been investigated as a diag-
nostic tool in breast cancer (40). Sinha 
et al. (41) were the first to demonstrate 
that ADC values could differentiate 
between normal, benign masses and 
malignancies in the breast. The range 
of b values reported in the literature 
for breast DWI is 0–1000. Two studies 
have investigated multiple combina-
tions of b values to determine their 
effect on image quality and the cal-
culated ADC value (42, 43). The first 
study found no significant difference 
in the diagnostic performance of ADC 
Figure 2. a, b. Transverse DWI (a) and corresponding ADC map (b) of  a 52-year-old patient with squamous cell carcinoma. The peripheral 
mass in the laterobasal segment of the right lower lobe appears hyperintense relative to the spinal cord on the DWI image (a, white arrow) and 
shows restricted diffusion (ADC value, 1.10x10-3 mm2/s) on the ADC map (b, black arrow). Note the inflammatory lesion in the left lower lung 
with unrestricted diffusion.
ba
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values obtained with different b value 
combinations and suggested that ADC 
values based on b values of 0 and 750 
were preferred (43). Another study 
concluded that b values of 50 and 850 
resulted in the highest accuracy (95%) 
(42). The optimum cut-off values var-
ied in these studies, which was likely a 
result of different calculation methods 
and differences in patient populations 
(43–45). Despite the ability of DWI to 
statistically differentiate benign from 
malignant breast lesions, there is typi-
cally a considerable overlap of values 
in the two groups. Recently, a study 
by Costantini et al. (46) reported an 
inverse relationship between ADC val-
ues and tumor grade. Less aggressive 
tumors (Grade 1 and in situ lesions) 
displayed an average ADC value of 
1.19×10-3 mm2/s, whereas more ag-
gressive tumors (Grades 2 and 3) had 
an average ADC value of 0.96×10-3 
mm2/s. Another study found a signifi-
cant correlation between the average 
ADC value of invasive ductal carcino-
ma of the breast and estrogen receptor 
(ER) and HER2 expression (47).
Another attempt to improve 
the diagnostic performance of 
diffusion-weighted MRI in breast MRI 
was embodied in the suggestion of 
El Khouli et al. (48) to normalize the 
ADC value of breast lesions to the ADC 
value of the ipsilateral remote glandu-
lar tissue (Fig. 3). The normalization is 
thought to overcome factors that affect 
ADC values, including ADC variations 
across the menstrual cycle (as reported 
previously by Partridge et al. [49]) and 
variations of scanning parameters. The 
normalized ADC value with a cut-off 
point of 0.7 significantly improved 
the diagnostic performance of DWI in 
discriminating benign from malignant 
lesions (48).
Reports have shown that ADC is 
useful in assessing the early (after the 
first cycle) (50) and late (after the third 
cycle) (51) tumor response to neoadju-
vant chemotherapy when compared 
with morphological parameters such 
as tumor volume (50) and dynamic 
contrast-enhanced MRI parameters 
(52). Investigators have reported an in-
crease in the ADC value of lesions after 
neoadjuvant chemotherapy. Sharma 
et al. (50) reported a 51%±31.5% in-
crease of the ADC value in responders 
and only a 14.3%±13.1% increase in 
nonresponders. The authors suggested 
a 15.7% cut-off value after two cycles 
with a sensitivity of 81%, a specificity 
of 88%, and an area under the curve 
(AUC) of 0.93. A 23.8% increase in 
the ADC was also suggested as a cut-
off value after three cycles of neoadju-
vant chemotherapy with a sensitivity 
of 79%, a specificity of 80%, and an 
AUC of 0.87. Park et al. (51) reported 
a 47.9%±4.8% increase in ADC in re-
sponders, whereas nonresponders 
demonstrated only an 18.1%±4.5% in-
crease. Pretreatment ADC values have 
also been investigated (51, 53). Nilsen 
et al. (53) did not find significant dif-
ferences between the pretreatment 
ADC values of responders and nonre-
sponders. On the other hand, Park et 
al. (51) reported that the pretreatment 
ADC values of responders were sig-
nificantly lower than those of nonre-
sponders and suggested a cut-off value 
of 1.17×10-3 mm2/s for the response, 
with a sensitivity of 94%, a specificity 
of 71%, and an AUC of 0.89.
Abdominal applications
The role of DWI in the abdomen has 
been relatively limited because of mo-
tion (respiration, peristaltic, and bulk) 
and susceptibility artifacts arising from 
gas in the bowel. With the develop-
ment of faster imaging techniques, the 
ability to produce satisfactory abdomi-
nal DWI has improved.
The ADC values of abdominal tu-
mors are variable because of differing 
amounts of cellularity, inflammation, 
and necrosis (54, 55) (Fig. 4). 
DWI is able to differentiate between 
benign and malignant focal hepatic 
lesions, in many cases because of the 
higher ADC of benign lesions com-
pared with malignant lesions (56–58). 
This finding is thought to be the result 
of cellular membranes impeding the 
mobility of water molecules. However, 
solid benign lesions, which are also 
highly cellular, also demonstrate de-
creased ADC values. When malignant 
liver lesions are cystic or necrotic, DWI 
is less useful (59).
To evaluate focal liver lesions with 
DWI, Holzapfel et al. (60) demon-
strated that DWI using a respiratory-
triggered SSEPI sequence (b values, 50, 
300, 600 s/mm2) permitted the charac-
terization of small (≤10 mm diameter) 
focal liver lesions as benign or malig-
nant with high accuracy and excellent 
interobserver agreement. In this study, 
Figure 3. a, b. A 43-year-old patient newly diagnosed with breast cancer. ADC map (a) (DWI 
was acquired with b values of 0 and 600 s/mm2, TR/TE/FA 9548/64/90). Axial computer-
aided detection (CAD) color map (b) generated by the pharmacokinetic analysis of dynamic 
contrast-enhanced MRI. The ADC map demonstrates the lesion heterogeneity with the 
low-signal region on the ADC map (restricted diffusion) corresponding to the regions with 
a suspicious perfusion pattern (red and green areas on the CAD color map) (arrows). The 
histopathological analysis of the lesion revealed in-situ and infiltrating ductal carcinoma.
ba
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application of a threshold ADC value 
of 1.41×10−3 mm2/s allowed the dif-
ferentiation of benign and malignant 
focal liver lesions with a sensitivity of 
90.8% and a specificity of 89.9%. The 
results of a recently published system-
atic meta-analysis by Xia et al. (61) 
indicated that DWI could be helpful 
in diagnosing malignant liver lesions. 
The use of DWI could increase the 
posttest probability from a baseline of 
25% to 81%, with a likelihood ratio 
of 13, and would reduce the post-test 
probability to as low as 3% when DWI 
was negative, with a likelihood ratio 
of 0.1. This analysis implies that DWI 
could be helpful in increasing the ac-
curate detection of malignant hepatic 
lesions (Fig. 5).
ADC values are less useful in patients 
with cirrhotic livers because cirrhosis 
and solid benign lesions also demon-
strate low ADC values, leading to con-
siderable overlap among disease cat-
egories. Necrosis and increased vascu-
larity within hepatocellular carcinoma 
(HCC) may also alter diffusion, lead-
ing to falsely high ADC values (62). 
Nevertheless, there are reports that 
DWI showed a higher sensitivity than 
conventional MRI in detecting HCC 
in the cirrhotic liver (98% for DWI 
vs. 83%–85% for MRI). For instance, 
Vandecaveye et al. (63) showed that 
DWI provided higher sensitivity and 
positive predictive values for the detec-
tion of HCC <20 mm compared with 
conventional contrast-enhanced MRI 
(sensitivity and specificity, 91.2% and 
82.9% vs. 67.6% and 61.6%; positive 
predictive values, 81.6% and 59.0%, 
respectively). However, DWI did not 
show significantly better results than 
conventional MRI in detecting HCC 
>20 mm. Thus, DWI provides a high 
negative predictive value for the pres-
ence of HCC and reduces the rate of 
unnecessary invasive diagnostic proce-
dures and follow-up.
Hepatic metastases are the most 
common neoplasms of the liver. The 
usefulness of DWI in detecting liver 
metastases has been demonstrated 
in several studies. Taouli et al. (57) 
showed that metastatic liver tumors 
had the lowest ADC among malignant 
and benign focal lesions of the liver 
and found a significant difference in 
ADC values between benign and ma-
lignant lesions. Feuerlein et al. (64) 
pointed out that the performance of 
DWI was contingent on the pretest 
Figure 4. a–c. A 40-year-old man with a hepatic cyst. The lesion is hypointense on the 
T1-weighted image (arrow) (a), hyperintense on the T2-weighted image (arrow) (b), and 
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probability of malignancy (e.g., DWI 
performed better in patients with 
high pretest probabilities). Nasu et 
al. (65) assessed the diagnostic ac-
curacy of respiratory-triggered DWI 
in combination with unenhanced 
MRI vs. superparamagnetic iron ox-
ide (SPIO)-enhanced MRI (66). Based 
on a receiver operator characteristic 
analysis averaged over three observ-
ers, the sensitivity and specificity for 
SPIO-enhanced images were 66% and 
90%, compared with 82% and 94% for 
DWI.
Overall, the utility of DWI for moni-
toring the treatment response in HCC 
and metastases is very promising and 
may provide the possibility of individ-
ualized treatments. Early detection of 
the systemic chemotherapy response 
based on DWI findings has been inves-
tigated in several studies, and systemic 
chemotherapy of liver metastases had 
a good correlation between response 
and increased ADC values following 
treatment (67). Chan et al. (68) showed 
that DWI could be used to distinguish 
between hepatic abscesses and cystic 
or necrotic malignant liver tumors; 
the ADC values of abscess cavities were 
lower than those of cystic or necrotic 
malignant liver tumors.
Within the pancreas, there is a dif-
ference in the ADC values of the head, 
body, and tail. The pancreatic head 
and body have slightly higher ADC 
values than the tail (69). DWI findings 
of pancreatic adenocarcinoma sug-
gest that ADC values are lower than in 
the normal pancreas, although there 
was considerable variability (70). The 
histopathological characteristics of 
tumors strongly influence the ADC 
values. When the tumor consists of 
prominent loose extracellular fibrosis 
(edematous fibrosis and loose collagen 
fibers) with a reduced cellular compo-
nent, the ADC values are higher than 
in the normal pancreas. When there 
is a dense fibrosis and increased cel-
lular elements, the ADC values are 
lower than in the normal pancreas 
(71). Pancreatic adenocarcinoma dem-
onstrates restricted diffusion in DWI 
compared with the rest of the gland, 
with a high b value (1 000 s/mm2). 
Utilizing ADC values, the mean sensi-
tivity and specificity were reported to 
be 96.2% and 98.6%, respectively (72). 
However, an overlap of ADC values 
between pancreatic adenocarcinoma 
and focal pancreatitis has been shown. 
Mass-forming focal pancreatitis has 
been shown to have either lower or 
higher ADC values than pancreatic ad-





Figure 5. a–d. A 65-year-old male with pancreatic adenocarcinoma and liver metastases. The dominant liver lesion in segment 6 is 
hypointense on the T1-weighted image (a, arrow), hyperintense on the T2- weighted image (b, arrow), hyperintense on DWI (c, arrow), 
and appears black on the PET-like diffusion-weighted image (d, arrow). The mean ADC value was 0.63 mm2/s. Also note additional smaller 
metastases in segments 4 and 5 on DWI (c, d, thick arrows).
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be indistinguishable from the ADC 
values in the remaining gland (70). 
Thus, DWI could be included as a com-
plement to the standard MRI protocol 
for the pancreas. As noted previously, 
the ADC values of simple cysts and 
pseudocysts tend to be higher than the 
ADC values of pancreatic abscesses, hy-
datid cysts, and neoplastic cysts (73). 
Intraductal mucin-producing tumors 
demonstrate ADC values comparable 
to those of other pancreatic cystic le-
sions (74).
Among normal abdominal organs, 
the highest ADC is found in the kidney, 
followed by the liver, pancreas, and 
spleen (69). The ADC values of the up-
per pole of the kidney are higher than 
those of the central portion, most likely 
due to the radial orientation of struc-
tures within the kidney, such as renal 
vessels and tubules (75). The signal in-
tensity of the most simple cysts drops 
significantly at a b value of 500 s/mm2 
and dissipates completely at b values of 
1 000–1 500 s/mm2. It has been shown 
that T1-hyperintense renal cysts and 
cystic masses (related to blood products 
or proteinaceous contents) have lower 
ADC values than their T1-hypointense 
counterparts (76). Manenti et al. (77) 
have reported significant differences 
among the ADC values of renal carcino-
mas and normal parenchyma; however, 
their analysis did not reveal a signifi-
cant difference in the mean ADC value 
of the individual histological variants 
of renal carcinoma. In another study, 
Paudyal et al. (78) demonstrated that 
ADC values were significantly higher 
in renal cell carcinomas (RCC) than in 
transitional cell carcinomas. Further 
analysis of the histological subtypes of 
RCC demonstrated that clear-cell car-
cinomas had lower ADC values than 
non-clear-cell carcinomas, most likely 
because of differences in cellularity.
MRI also has been used to character-
ize adrenal masses as adrenal adeno-
mas or malignancies. However, there 
are limited studies on the characteri-
zation of benign and malignant adre-
nal lesions using DWI. The signal in-
tensity characteristics of up to 30% of 
benign adrenal adenomas may over-
lap with those of malignant lesions 
with conventional MRI (77), and it is 
not clear whether DWI can help dif-
ferentiate between these two groups. 
According to recent studies, benign 
adrenal lesions could not be distin-
guished from malignant lesions with 
DWI because of a considerable over-
lap in ADC values (79). Importantly, 
DWI did not help distinguish lipid-
poor from lipid-rich adenomas or dis-
tinguish between lipid-poor adenom-
as and other non-fatty lesions of the 
adrenal gland. 
It has been shown that DWI has 
a greater sensitivity and specificity 
than MR cholangiopancreatography 
(MRCP) in the detection of extrahe-
patic cholangiocarcinoma (80). Cui et 
al. (80) concluded that the detection 
rate of extrahepatic cholangiocarcino-
ma was significantly higher for DWI 
(94.3%) than for MRCP (74.3%), and 
the positive and negative predictive 
values of DWI (100%, 91.3%) were 
higher than those of MRCP (81.3%, 
62.5%). Additionally, DWI was found 
to be a useful technique for screening 
peritoneal dissemination in a cohort 
of 107 patients with primary gastroin-
testinal or genitourinary tract malig-
nancies (81).
Male pelvis applications
DWI applications in the male pelvis 
mainly focus on the imaging work-up 
of prostate cancer, especially in the era 
of serum prostate-specific screening. 
Normal prostate tissue is rich in glan-
dular tissue, which has higher water 
diffusion rates. These differences can 
be depicted on ADC maps obtained 
with multiple b field gradient values. 
Because DWI is an intrinsically low sig-
nal-to-noise sequence with noisy imag-
es and susceptibility artifacts, it benefits 
from higher field strengths and surface 
coils. However, higher field strengths 
can also introduce more challenges re-
garding susceptibility effects. The use 
of higher b values (0 to 1 000 and 2 000 
s/mm2) can improve lesion detection at 
the expense of a lower signal-to-noise 
ratio (82–85). Prostate cancer lesions 
demonstrate hyperintense signal char-
acteristics compared with the healthy 
peripheral zone on raw DWI, whereas 
they show a decreased signal intensity 
relative to healthy peripheral zone on 
ADC maps (86). DWI has demonstrat-
ed a wide range of sensitivities and spe-
cificities (57%–93.3% and 57%–100%, 
respectively) for tumor detection in 
various studies, depending on the field 
strength, imaging parameters, patient 
Figure 6. a, b. A 70-year-old man with prostate cancer. The axial T2W MR image (a) demonstrates a hypointense lesion in the right apical 
peripheral zone (arrow); an ADC map (b) derived from DWI localizes the tumor (arrow).
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selection, and validation method used 
(84, 87–92). In addition to their tumor 
detection capability, ADC values have 
recently been shown to be useful in dif-
ferentiating aggressive prostate cancers 
from indolent ones (93–96). DWI has 
a low signal noise ratio (SNR), but the 
emergence of high-field-strength mag-
nets, the widespread use of endorectal 
coils and parallel imaging approaches 
will yield better SNR and, therefore, 
better spatial/temporal resolution for 
DWI. Additionally, the use of higher 
gradient strengths (e.g., b values of 
1 000 to 2 000 s/mm2) improves the 
performance of DWI for lesion detec-
tion (83–85, 97). Moreover, DWI cur-
rently stands as the most promising 
quantitative MRI technique for im-
proving our understanding of the na-
ture of prostate cancer lesions (Fig. 6).
DWI has recently been reported to be 
useful in the detection and T-staging of 
bladder cancer. Matsuki et al. (98) re-
ported that the ADC values of bladder 
cancers were lower than those of the 
surrounding normal tissues, includ-
ing the bladder wall, in a cohort of 
15 patients. El-Assmy et al. (99) con-
firmed these results. Abou-El-Ghar et 
al. (100) reported a high sensitivity and 
positive predictive value of 98.5% and 
100%, respectively, in 106 consecutive 
patients presenting with hematuria. 
Watanabe et al. (101) concluded that 
DWI has a higher specificity for Stage 
T2 or higher tumors, whereas Takeuchi 
et al. (102) reported improvements in 
both diagnosis and staging by adding 
DWI to conventional T2W MRI and 
gadolinium-enhanced MRI. The cur-
rent literature on DWI use in bladder 
cancer is limited, but DWI remains a 
potentially useful adjunct (103).
Female pelvis applications
In the female pelvis, high-b-value 
(750–1 000 s/mm2) DWI images and 
ADC maps should be interpreted with 
anatomic images to make a correct 
evaluation and avoid pitfalls (2, 104, 
105).
The uterus and ovaries undergo mor-
phological changes during the men-
strual cycle, pregnancy and aging. The 
normal uterine corpus has three dis-
tinct zones on T2W images: the high-
intensity endometrial zone, the low-in-
tensity junction zone and the interme-
diate-intensity myometrium. Similar 
zonal anatomy can be observed on an 
ADC map. Because the ADC value is 
affected by cell type, cellular packing, 
intracellular elements, membranes, 
macromolecules and microcirculation, 
menstrual cycle-specific physiological 
changes in the structures of different 
uterine zones may affect the width 
and signal intensity of each layer. The 
mean ADC value of the myometrium 
and endometrium tends to be lower at 
the end of the menstrual cycle than in 
other phases. Of course, it can be diffi-
cult to determine the timing of an MR 
scan relative to menstrual cycle phases 
in clinical practice. An accurate evalu-
ation of low-intensity myometrial le-
sions, such as adenomyosis and leio-
myoma, requires MRI to be performed 
during the late proliferative and secre-
tory phases. The difference in the ADC 
values between malignant and non-
malignant lesions is comparable to the 
variation in the ADC values of normal 
structures during the menstrual cycle. 
Thus, the phase of the menstrual cycle 
must be considered when character-
izing or monitoring lesions with ADC 
(104, 106, 107).
DWI imaging of endometrial tumors 
has decreased ADC values (108–116). 
Endometrial carcinoma is clearly depict-
ed as an area of increased signal inten-
sity relative to the surrounding hypoin-
tense myometrium on DWI (116). ADC 
measurements have the potential to 
quantitatively differentiate Stage IA en-
dometrial carcinoma from normal en-
dometrium, endometrial dysplasia and 
benign diseases of the endometrium, 
such as endometrial hyperplasia, adeno-
myosis, submucosal leiomyoma, and 
endometrial polyps (108–116). DWI and 
combined DWI/T2W MRI can increase 
the overall detection sensitivity for en-
dometrial carcinoma (113). Although 
lower ADC values in high-grade tumors 
have been reported, some studies have 
reported no correlation between ADC 
values and histological grades (115, 
116). DWI is accurate for differentiating 
stage IB from stage IC and can be used as 
an adjunct for routine T2W MRI during 
pre-operative evaluation of endometrial 
cancer (111, 117).
The mean ADC value of cervical 
cancer lesions is lower than that of 
normal cervical tissue (112, 118–126). 
Hoogendam et al. (120) evaluated five 
different b value combinations and 
found that the ADC-based differentia-
tion of benign from malignant cervi-
cal tissue is independent of the tested 
b value combination. Because the ADC 
values calculated by DWI data sets are 
acquired with a minimum of two dif-
ferent b values, the b value combina-
tion can also affect the ADC value. 
Therefore, imaging parameters and 
b values should be considered when 
evaluating optimal ADC cut-off values 
to differentiate benign from malignant 
lesions (120). The ADC value of cervical 
squamous carcinoma was statistically 
lower than that of adenocarcinoma, 
and the ADC value of uterine cervical 
cancer correlated positively with differ-
entiation and negatively with cellular 
density and tumor grade (121, 122). Pre-
treatment ADC values of uterine cervi-
cal cancer were significantly lower in 
patients who had a complete response 
with combined chemoradiation com-
pared with patients who had a partial 
response (ADC values 0.80±0.07×10−3 
mm2/s, 0.93±0.09×10−3 mm2/s) (127). 
McVeigh et al. (124) found similar re-
sults, as pretreatment ADC values were 
lower in responders than nonrespond-
ers with squamous cell carcinoma (P < 
0.05). Harry et al. (128) did not find a 
correlation between pretreatment ADC 
values and tumor response. However, 
both ADC values and the change in 
ADC values after two weeks of therapy 
showed a significant correlation with 
eventual MRI and clinical response. It 
was concluded that DWI has the po-
tential to provide a surrogate biomarker 
of treatment response in advanced cer-
vical cancers. ADC values also signifi-
cantly increased after treatment (123, 
125–127). A prospective study of 61 
patients with cervical cancer showed 
that all lymph nodes with a short-axis 
diameter larger than 5 mm were de-
tected by DWI, regardless of whether 
they were benign or metastatic. The 
mean ADC values of enlarged meta-
static lymph nodes (short-axis diameter 
larger than 5 mm) were significantly 
lower than those of hyperplastic nodes 
(1.05±0.20×10−3 mm2/s, 1.29±0.19×10−3 
mm2/s, P < 0.001) (129). Park et al. 
(130) investigated the feasibility of us-
ing ADC values and relative ADC (us-
ing the renal cortex as the reference 
site) to differentiate metastatic from 
nonmetastatic lymph nodes in cervical 
carcinoma and found similar results. 
Because ADC values vary according to 
numerous factors, such as MR acquisi-
tion parameters and magnetic field, the 
use of relative ADC can improve the di-
agnostic accuracy of DWI for detecting 
metastatic lymph nodes (130–132). Lin 
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et al. (132) found that the combination 
of size and relative ADC values resulted 
in better sensitivity (25% vs. 83%) and 
similar specificity (98% vs. 99%) com-
pared with conventional MRI. Primary 
tumor type (adenocarcinoma vs. ad-
enosquamous carcinoma), focal infil-
tration with micrometastasis and asso-
ciated necrosis also affect ADC values, 
and overlap between hyperplastic and 
metastatic lymph nodes could occur 
(119, 129–134).
The presence of an enhancing solid 
component in ovarian tumors may 
suggest malignancy; however, it is of-
ten difficult to differentiate malignan-
cies from benign solid or cystic tumors 
with routine MRI. Takeuchi et al. (135) 
investigated the feasibility of using 
DWI to differentiate between benign 
and malignant ovarian tumors. The 
solid portion of the malignant tumors 
showed homogenous or heterogenous 
high intensity on DWI with low ADC 
values comparable to those of benign 
tumors. However, 30% of thecomas 
also showed high intensity on DWI 
with low ADC values. Fujii et al. (136) 
investigated the DWI characteristics 
and ADC values of 123 ovarian tumors 
(42 malignant, 81 benign) and reported 
that the majority of malignant ovarian 
tumors and mature cystic teratomas, 
and almost half of the endometriomas, 
showed abnormal signal intensity on 
DWI, whereas most fibromas and other 
benign lesions did not. The main loca-
tions of abnormal signal intensity were 
solid portions in malignant ovarian tu-
mors, cystic components suggestive of 
keratinoid substances and Rokitansky 
protuberances in mature cystic terato-
mas and intracystic clots in endome-
triomas. No significant difference was 
found in the mean and lowest ADC 
values of malignant and benign le-
sions, and it was concluded that DWI 
of ovarian lesions and the ADC values 
of the solid components are not useful 
for differentiating benign from malig-
nant ovarian lesions. The reported ADC 
values in malignant ovarian tumors 
ranged between 0.88×10−3 mm2/s and 
2.28×10−3 mm2/s (135–141). This vari-
ability in ADC values is probably due 
to tumor type, imaging parameters, b 
value combination, and region of inter-
est placement (whether or not the solid 
part was included). Low intensity on 
DWI with high ADC may suggest be-
nign lesions; however, it may be occa-
sionally difficult to differentiate benign 
from malignant lesions only on the ba-
sis of DWI (135). DWI provides a high 
contrast-to-noise ratio and enhanced 
detectability of even small malignant 
deposits. The combined interpretation 
of DWI and conventional MRI has been 
shown to increase accuracy in the stag-
ing of ovarian cancer by detecting more 
sites of peritoneal  involvement (142). 
Because of its noninvasive nature 
and ability to provide valuable quali-
tative and quantitative information, 
DWI has evolved into a diagnostically 
useful oncologic body imaging tool for 
lesion detection and characterization 
as well as treatment monitoring. The 
current evidence is sufficiently robust 
to support the incorporation of DWI 
into routine MRI. However, the stand-
ardization of data acquisition and anal-
ysis methods is necessary to achieve 
more reproducible results in both the 
detection and follow-up of neoplasms.
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